Firebrick Pharma Ltd

Firebrick Pharma Limited is an Australia-based pharmaceutical company. The principal activity for the Company is the clinical development and partnering of Nasodine, a broad-spectrum antimicrobial spray for the treatment of the common cold. The Company has developed a povidone-iodine nasal spray, called Nasodine Nasal Spray and filed international trademarks and multiple patents on the product, including a formulation patent and two use patents, some of which have already been granted in the United States, Europe and Australia. The Company has also completed six clinical trials for Nasodine, including a Phase I study, three Phase II studies and two Phase III studies, which have affirmed the product’s safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings. Nasodine Phase II COVID-19 trail achieves primarily endpoints.